Novo Nordisk Boosts Shareholder Return with New Repurchase Program
Novo Nordisk's Board of Directors has authorized a DKK 15 billion share repurchase program. At the AGM on March 26, 2026, a final dividend of DKK 7.95 per share is proposed, bringing the total expected dividend for 2025 to DKK 11.70.
Novo Nordisk's Board of Directors has announced a strategic move to initiate a share repurchase program worth DKK 15 billion. This decision aims to enhance shareholder value by returning capital to investors.
The company will propose a final dividend at the upcoming AGM on March 26, 2026. Shareholders can expect a DKK 7.95 per share dividend, contributing to a total anticipated payout of DKK 11.70 for 2025.
This action underscores Novo Nordisk's commitment to providing robust financial returns to its shareholders and maintaining investor confidence in the company's long-term growth strategy.
Advertisement
ALSO READ
-
Wegovy Woes: Novo Nordisk Faces Profit Slump Amid Fierce Competition
-
Leadership Shuffle at Novo Nordisk: A Strategic Shift
-
Leadership Changes at Novo Nordisk: A Strategic Move
-
Novo Nordisk Revamps Leadership with Key Appointments in the U.S. Operations
-
Novo Nordisk Fights to Reclaim Obesity Drug Market Amid Declining Sales
Google News